Morris K. Udall Centers of Excellence for Parkinsons Disease Research (P50)

Post Date

October 6th 2009

Application Due Date

December 10th 2009

Funding Opportunity Number

RFA-NS-10-001

CFDA Number(s)

93.853

Funding Instrument Type(s)

Grant

Funding Activity Categories

Health

Number of Awards

4

Eligibility Categories

Public and State Controlled Institutions of Higher Education
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs) .

Funding

• Estimated Total Funding:

  $9000000

• Award Range:

  $None - $None

Grant Description

Purpose. The National Institute of Neurological Disorders and Stroke (NINDS) invites new and competing renewal applications for the Morris K. Udall Centers of Excellence for Parkinsons Disease Research program. Proposed Centers must involve multidisciplinary teams engaged in integrative basic, translational and clinical research on Parkinsons disease (PD), with the primary objective of transforming this research into the development of new treatments. Investigations on related parkinsonian disorders may be included, to the extent that these inform and/or expand research on PD. Accomplishment of the stated goals of the Center, and of each project, must require substantial collaborative efforts and the utilization of common resource cores. All proposed Centers must include a pre-clinical and/or clinical translational research project. In this context, pre-clinical translation is defined as pre-IND/IDE (Investigational New Drug/Investigational Device Exemption) stage research on potential therapeutic or diagnostic candidates. Clinical translational projects are early-stage projects in human subjects that are designed as first steps toward transformation of scientific discoveries arising from basic research, clinical research or population studies into new modalities for the prevention, treatment and cure of PD. All Centers are required to have an Administrative Core; inclusion of other research and core components is flexible within stated budget limits. Inclusion of a clinical component, a clinical translational research project plus a clinical resource core, is encouraged, as is emphasis on training and public outreach activities. The Udall Center Director (PI) must be an established leader in scientific research with visionary leadership skills and proven expertise in research project and personnel management. Eligible institutions must demonstrate commitment to and support for the establishment and continuation of the proposed Udall Center. Successful applicants will participate in a network of existing Udall Centers to foster the translation of new scientific findings and technological developments into novel treatments for PD.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-10-001.html